Published in OBGYN and Reproduction Week, November 3rd, 2008
"A private tertiary care-hospital assisted reproduction program. Ten women at high risk for OHSS (mean E-2 level 9401 +/- 585 pg/mL on the day of hCG administration). Cancellation of ET and dual RAS blockage with an angiotensin receptor blocker (candesartan cilexetil) and an angiotensin-converting enzyme inhibitor (enalapril) starting...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of OBGYN and Reproduction Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.